Home > Cardiology > ACC 2021 > Interventional and Structural Cardiology > TALOS-AMI: Exploring outcomes after switching to clopidogrel versus ticagrelor at 1 month from MI

TALOS-AMI: Exploring outcomes after switching to clopidogrel versus ticagrelor at 1 month from MI

Presented By
Prof. Kiyuk Chang, Seoul St. Mary’s Hospital, South Korea
Conference
ACC 2021
Trial
TALOS-AMI
The open-label, non-placebo controlled TALOS-AMI study raises the hypothesis that net outcomes (i.e. bleeding and ischaemic) may be similar in selected patients by switching at 1 month from myocardial infarction (MI) [1]. The risk of thrombosis is highest in the first 30 days following acute MI. Bleeding is also higher; however, the curve may be less steep depending on patient bleeding risk and experience with prior antithrombotics,  (see Figure) [2]. Currently, patients who have experienced acute MI followed by PCI receive DAPT with aspirin and a P2Y12 inhibitor. It was unknown whether de-escalation to a less potent, more variable  P2Y12 inhibitor following the 30-day post-PCI would be associated with less bleeding. Figure: The risk of thrombosis versus bleeding following acute myocardial infarction [2]


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on